Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liquid Metformin Tolerability Study
NCT07300046Phase 1Not yet recruiting
- Sponsor
- Aspargo Laboratories
- Start
- Jun 2026
- Primary completion
- Aug 2026
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM), sponsored by Aspargo Laboratories. Primary endpoint: Incidence of Gastrointestinal Treatment-Emergent Adverse Events at 24 hours. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07300046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07300046.